| Abstrakt: |
Onkos Surgical, an orthopaedic company, has received FDA approval for its antibacterial coated implants. The coating has been shown to be bactericidal, with a 99.999% kill rate in in-vitro testing. The technology aims to reduce bacterial contamination of implants, which can have devastating effects on patients, particularly in orthopedic oncology and revision arthroplasty applications. While the effectiveness of the technology has not been proven in human clinical trials, it is seen as a significant innovation in the field of orthopedic medical devices. [Extracted from the article] |
